US20100311967A1 - Production of bepromoline - Google Patents

Production of bepromoline Download PDF

Info

Publication number
US20100311967A1
US20100311967A1 US12/858,273 US85827310A US2010311967A1 US 20100311967 A1 US20100311967 A1 US 20100311967A1 US 85827310 A US85827310 A US 85827310A US 2010311967 A1 US2010311967 A1 US 2010311967A1
Authority
US
United States
Prior art keywords
hcl
formula
compound
bepromoline
amorolfine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/858,273
Other versions
US8242268B2 (en
Inventor
Beat Weber
Stefan Rosenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Holding SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma SA filed Critical Galderma SA
Priority to US12/858,273 priority Critical patent/US8242268B2/en
Publication of US20100311967A1 publication Critical patent/US20100311967A1/en
Application granted granted Critical
Publication of US8242268B2 publication Critical patent/US8242268B2/en
Assigned to Galderma Holding SA reassignment Galderma Holding SA CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: Nestlé Skin Health S.A.
Assigned to Nestlé Skin Health S.A. reassignment Nestlé Skin Health S.A. ASSET TRANSFER AGREEMENT Assignors: GALDERMA S.A.
Assigned to Galderma Holding SA reassignment Galderma Holding SA CHANGE OF ADDRESS Assignors: Galderma Holding SA
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/023Preparation; Separation; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms

Definitions

  • the present invention relates to an improved process of producing bepromoline hydrochloride (bepromoline HCl), which is an intermediate used in the production of Amorolfine (AMF) hydrochloride (Amorolfine HCl).
  • Amorolfine HCl is an active pharmaceutical ingredient (API) formulated into topical anti-mycotic (anti-fungal) compositions.
  • the suggested catalysts are those generally employed for hydrogenation, with specific mention of platinum, palladium, palladiumcarbon or Raney nickel catalysts. No indication is made of the pH of the hydrogenation conditions.
  • Need continues to exist for improved processes for the production of Amorolfine salts, for example Amorolfine HCl, notably through an improvement in the production of its intermediates, such as bepromoline or a salt of bepromoline as, for example, bepromoline HCl.
  • bepromoline base refers to the compound of formula (Ia)
  • bepromoline HCl refers to the compound of formula (Ib)
  • Amorolfine HCl refers to the compound of formula (II):
  • the present invention relates to an improved process for producing bepromoline HCl, an intermediate in the production of AMF HCl.
  • This acetic acid addition (step (ii)) is for the reduction of the C ⁇ N double bond under hydrogen pressure.
  • step (i) is conducted under basic conditions and acetic acid added once the consumption of hydrogen gas has ceased.
  • step (i) The reduction under hydrogen pressure of the C ⁇ C double bond is better conducted under basic conditions (step (i)), and once the consumption of hydrogen gas has ceased, the reduction under hydrogen pressure of the C ⁇ N double bond is better conducted under acetic conditions (step (ii)).
  • a preferred process according to the invention is a process of preparing bepromoline base, which is a compound of formula (Ia):
  • step (i) is conducted under basic conditions, and (ii), once the consumption of hydrogen gas has ceased, acetic acid is added.
  • the palladium catalyst comprises palladium precipitated onto carbon.
  • the basic conditions are provided by potassium hydroxide, although other alkalis can also be used. It has been found that the inclusion of 1.5 to 2.0 mol % potassium hydroxide, typically about 1.8 mol % potassium hydroxide, is sufficient.
  • said process comprising a process described above for the first embodiment of the invention followed by the following step: (iii) contacting the compound of formula (Ia) with toluene and HCl gas to produce a compound of formula (Ib).
  • the toluene and HCl gas are added at a temperature of up to 50° C.
  • the process of preparing a compound of formula (Ib) includes one or more of the following steps:
  • step (a) entails:
  • the solubilization of the compound of formula (Ia) in toluene followed by acidification with hydrochloric acid are particularly useful, because this step avoids distillation of the compound of formula (Ia), which is long-time consuming.
  • the solid hydrochloride salt of formula (Ib) obtained in toluene is easier to handle than the liquid compound of formula (Ia) and can be directly employed in the following reaction.
  • process comprising a process described above for any of the first, or second embodiment of the present invention.
  • bepromoline HCl (compound (Ib)) can be contacted with, for example, FeCl 3 , and then added to 2-chloro-2-methylbutane.
  • bepromoline base (compound (Ia)
  • bepromoline HCl can be converted to bepromoline HCl by a salification step, and then submitted to the same reactions as herein above described (contact with for example FeCl 3 , and then addition to 2-chloro-2-methylbutane).
  • the process of the third embodiment further includes the step of reacting a compound of formula (Ib) with 2-chloro-2-methylbutane in the presence of FeCl 3 as Friedel-Crafts catalyst.
  • the Friedel-Crafts catalyst will usually be embodiment in a suitable solvent, for example dichloromethane (DCM).
  • a suitable solvent for example dichloromethane (DCM).
  • the compound of formula (Ib) is contacted with the Friedel-Crafts catalyst at room temperature.
  • the 2-chloro-2-methylbutane is added to the compound of formula (Ib) at a temperature of ⁇ 40° C. to ⁇ 60° C., for example ⁇ 50° C.
  • a process for preparing a compound of formula (II) comprising the process of any of first, second, or third embodiments of the invention.
  • the process for preparing a compound of formula (II) further comprises the step of crystallizing AMF HCl from addition of HCl to a solution of AMF base in ethanol.
  • the present invention also features the compound of formula (Ia) (bepromoline base) or to compound of formula (Ib) (bepromoline HCl), each of these compounds having a purity degree superior or equal to 99.5%.
  • a mixture of one part of ⁇ -methyl-cinnamaldehyde to one part of cis-2,6-dimethyl-morpholine (DMM) is hydrogenated in methanol in the presence of catalytic amount of palladium on carbon, optionally under basic conditions until the uptake of H 2 gas ceases, this indicating completion of the reduction of the C ⁇ C double bond.
  • Acetic acid is then added for the reduction of the C ⁇ N double bond under hydrogen pressure; the C ⁇ N double bond is formed between the aldehyde and the amino moiety of the two reactants, ⁇ -methyl-cinnamaldehyde and DMM, respectively.
  • the catalyst is then filtered off and the methanol is removed by distillation.
  • Toluene is added and the inorganic components are removed by washing with water.
  • Toluene and unreacted DMM are distilled off.
  • fresh toluene and HCl gas are added and the pH is adjusted to 3-4.
  • the bepromoline HCl is centrifuged and dried.
  • Methanol may be substituted by toluene to avoid the later solvent exchange step.
  • 40° C. is the optimum temperature for both hydrogenation steps.
  • the temperature may typically be set at no more than 45° C., preferably between 30° C. and 45° C.
  • the reduction for the C ⁇ N double bond formed between the aldehyde and the amino function of the two components is conducted under hydrogen pressure in acidic conditions after the addition of acetic acid.
  • a molar ratio of acetic acid to KOH is around 1.3 ( ⁇ 10%).
  • the acetic acid is typically added at a temperature range of between 40° C. to 45° C., and no more than 45° C.
  • the toluene is advantageously added to facilitate the phase separations and the distillation step of the unreacted DMM, thus improving the purity of bepromoline.
  • the purity of the bepromoline HCl (cis isomer) is superior or equal to 99.5%.
  • the product is stable up to 150° C.
  • a reactor was charged with 146 kg a-methyl-cinnamaldehyde, 115 kg cis-2,6-dimethyl-morpholine, 2.1 kg 50% KOH, 278 kg methanol and 5.8 kg of a palladium/carbon catalyst and then filled with hydrogen at 15-25° C.
  • the hydrogenation was then conducted at a pressure of ⁇ 2 bar and 35-45° C. until H 2 consumption ceased.
  • reaction mixture was filtered and the catalyst washed with methanol and water.
  • the solvents were distilled off at a temperature of up to 95° C. under vacuum.
  • the reactor was charged with 904 kg toluene and 33 kg HCl gas at a temperature of up to 50° C. Then the pH was adjusted to 3-4. The reaction mixture was cooled and then stored sufficiently to reached complete crystallization.
  • the mixture was centrifuged and washed with cold (0-5° C.) toluene. A second crop of Bepromoline HCl was isolated from the mother liquor.
  • the process yielded 287 kg wet bepromoline HCl, which was then dried at 60° C. under vacuum. After drying, the first crop of Bepromoline HCl was 227 kg and the second 18 kg. This corresponds to a yield of 87% (80% for the first crop Bepromoline HCl and 7% for the second crop).
  • reaction mixture is poured onto an ice-water mixture.
  • the organic phase is separated and washed with acidic water, and then with sodium phosphate solution and with sodium hydroxide solution. After a stripping with toluene, extractions with water are performed. The solvent is then removed. Then the residue is distilled.
  • a suitable molar ratio of FeCl 3 to bepromoline is 1:2 to 1:5 equivalents of catalyst. 1.3 equivalents of FeCl 3 are preferred.
  • the reaction is conducted at low temperature, preferably ⁇ 50° C. (see Table 2):
  • FPM Fenpropimorph
  • FPM Fenpropimorph
  • the Amorolfine HCl (which is in the DCM) is converted to the free base during these extractions. Phosphate was used to remove traces of Fe.
  • the reactor was charged with 212 kg FeCl 3 and 757 kg DCM. 284 kg bepromoline HCl in 946 kg DCM were added to the reactor at 20-30° C. The reaction mixture was completed with 213 kg DCM and cooled to ⁇ 50° C. 107 kg 2-chloro-2-methylbutane in 107 kg DCM were added at ⁇ 50° C., although a temperature of ⁇ 60 to ⁇ 45° C. is acceptable, and stirred for 2.5 hours.
  • Extractions using slightly acidic water (water and diluted HCl) were performed, followed by a further extraction with a solution of Na 3 PO 4 in water.
  • a subsequent extraction was conducted using NaOH diluted in water to a pH ⁇ 13.
  • pH ⁇ 13 At a lower pH value there is incomplete HCl removal, leading to distillation problems.
  • Two washes were performed with water.
  • the solvent was distilled off.
  • the distillation step is necessary to purify Amorolfine Base.
  • AMF base Apart from FPM, all impurities present in AMF base are removed firstly by the salification of AMF base into AMF HCl and secondly by one crystallization step from ethanol.
  • the temperature raises by around 35° C. This exotherm is used to warm the batch. After the addition of HCl the temperature is raised to a level that ensures that the reaction mixture is in solution.
  • the final temperature of ⁇ 20 to ⁇ 15° C. is important to obtain an optimum yield.
  • Ethanol is the preferred solvent.
  • the Amorolfine HCl is dissolved in hot ethanol and this solution is filtered to remove foreign matter. The filtrate is then cooled to ⁇ 15 to ⁇ 20° C. to get the optimum yield of crystallization. After centrifugation, the crystals are washed with an appropriate amount of ethanol.
  • the Amorolfine HCl is stable up to 150° C. Drying conditions of 60° C. in a vacuum are used and do not 25 produce any problems with the residual solvent.
  • the reactor was charged with 317 kg AMF and 640 kg ethanol. 38 kg HCl gas was added at 10-65° C. The reaction mixture was then heated to 60° C., followed by cooling to ⁇ 15 to ⁇ 20° C. The mixture was stored for 30 minutes to 2 hours.
  • the Amorolfine HCl was centrifuged and washed with 210 kg of ethanol.
  • the hot solution was filtered and the filter rinsed. with 15 kg hot ethanol.
  • the filtrate was then cooled to ⁇ 15 to ⁇ 20° C. and stored for 30 minutes to 2 hours.
  • the crystallized Amorolfine HCl was centrifuged and washed with 210 kg of ethanol.
  • the mixture was then dried at a temperature of 60° C. under vacuum ( ⁇ 100 mbar).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

A process for the preparation of a compound of formula (Ib):
Figure US20100311967A1-20101209-C00001
including contacting a compound of formula (Ia):
Figure US20100311967A1-20101209-C00002
with toluene and HCl gas to provide the compound of formula (Ib).

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional application of application Ser. No. 12/010,635, filed Jan. 28, 2008, which is a continuation of PCT/IB 2006/003362, filed Jul. 27, 2006 and designating the United States (published in the English language on Feb. 1, 2007 as WO 2007/012984 A2), which in turn claims priority under 35 U.S.C. §119 of EP 05291611.1, filed Jul. 28, 2005, each hereby expressly incorporated by reference in its entirety and each assigned to the assignee hereof.
  • BACKGROUND OF THE INVENTION
  • 1. Technical Field of the Invention
  • The present invention relates to an improved process of producing bepromoline hydrochloride (bepromoline HCl), which is an intermediate used in the production of Amorolfine (AMF) hydrochloride (Amorolfine HCl).
  • Amorolfine HCl is an active pharmaceutical ingredient (API) formulated into topical anti-mycotic (anti-fungal) compositions.
  • 2. Description of Background and/or Related and/or Prior Art
  • French Patent No 2,463,767 describes methods of producing Amorolfine HCl and intermediates for such production. In particular, a method for the production of bepromoline base of formula (Ia):
  • Figure US20100311967A1-20101209-C00003
  • is described, this method involving the step of reacting a compound of the formula (III):
  • Figure US20100311967A1-20101209-C00004
  • with a compound of the formula (IV):
  • Figure US20100311967A1-20101209-C00005
  • such that they undergo catalytic hydrogenation to produce bepromoline base. The suggested catalysts are those generally employed for hydrogenation, with specific mention of platinum, palladium, palladiumcarbon or Raney nickel catalysts. No indication is made of the pH of the hydrogenation conditions.
  • Need continues to exist for improved processes for the production of Amorolfine salts, for example Amorolfine HCl, notably through an improvement in the production of its intermediates, such as bepromoline or a salt of bepromoline as, for example, bepromoline HCl.
  • As employed herein, the term “bepromoline base” refers to the compound of formula (Ia), the term “bepromoline HCl” refers to the compound of formula (Ib), and the term “Amorolfine HCl” (AMF HCl) refers to the compound of formula (II):
  • Figure US20100311967A1-20101209-C00006
  • SUMMARY OF THE INVENTION
  • The present invention relates to an improved process for producing bepromoline HCl, an intermediate in the production of AMF HCl.
  • According to a first embodiment of the invention, there is provided a process of preparing bepromoline base, which is a compound of formula (Ia):
  • Figure US20100311967A1-20101209-C00007
  • said process comprising:
    (i) contacting a compound of formula (III):
  • Figure US20100311967A1-20101209-C00008
  • with a compound of formula (IV):
  • Figure US20100311967A1-20101209-C00009
  • in the presence of a palladium catalyst, methanol and hydrogen gas, wherein (ii), once the consumption of hydrogen gas has ceased, acetic acid is added.
  • This acetic acid addition (step (ii)) is for the reduction of the C═N double bond under hydrogen pressure.
  • DETAILED DESCRIPTION OF BEST MODE AND SPECIFIC/PREFERRED EMBODIMENTS OF THE INVENTION
  • More preferably, step (i) is conducted under basic conditions and acetic acid added once the consumption of hydrogen gas has ceased.
  • The reduction under hydrogen pressure of the C═C double bond is better conducted under basic conditions (step (i)), and once the consumption of hydrogen gas has ceased, the reduction under hydrogen pressure of the C═N double bond is better conducted under acetic conditions (step (ii)).
  • Consequently, a preferred process according to the invention is a process of preparing bepromoline base, which is a compound of formula (Ia):
  • Figure US20100311967A1-20101209-C00010
  • said process comprising:
    (i) contacting a compound of formula (III):
  • Figure US20100311967A1-20101209-C00011
  • with a compound of formula (IV):
  • Figure US20100311967A1-20101209-C00012
  • in the presence of a palladium catalyst, methanol and hydrogen gas, wherein step (i) is conducted under basic conditions, and (ii), once the consumption of hydrogen gas has ceased, acetic acid is added.
  • Compounds of formulae (III) and (IV) are termed herein “α-methylcinnamaldehyde” and “cis-2,6-dimethyl morpholine” (DMM), respectively.
  • In one embodiment, the palladium catalyst comprises palladium precipitated onto carbon.
  • Typically, the basic conditions are provided by potassium hydroxide, although other alkalis can also be used. It has been found that the inclusion of 1.5 to 2.0 mol % potassium hydroxide, typically about 1.8 mol % potassium hydroxide, is sufficient.
  • Generally, the compounds of formulae (III) and (IV) are added in approximately equimolar proportions.
  • According to a second embodiment of the present invention, there is provided a process for preparing a compound of formula (Ib):
  • Figure US20100311967A1-20101209-C00013
  • said process comprising a process described above for the first embodiment of the invention followed by the following step: (iii) contacting the compound of formula (Ia) with toluene and HCl gas to produce a compound of formula (Ib).
  • In one embodiment, the toluene and HCl gas are added at a temperature of up to 50° C.
  • In another embodiment, the process of preparing a compound of formula (Ib) includes one or more of the following steps:
  • (a) purifying the compound of formula (Ia);
  • (b) adding fresh toluene and HCl gas;
  • (c) adjusting the pH to 3 to 4;
  • (d) cooling to 0 to 5° C.;
  • (e) stirring for at least 1 hour; and
  • (f) isolating the end product of formula (Ib).
  • In another embodiment, step (a) entails:
  • (a1) filtering and washing the catalyst with methanol and water;
  • (a2) removing any used methanol;
  • (a3) adding toluene and extracting inorganic components using water; and
  • (a4) removing used toluene and unreacted DMM.
  • According to the present invention, the solubilization of the compound of formula (Ia) in toluene followed by acidification with hydrochloric acid are particularly useful, because this step avoids distillation of the compound of formula (Ia), which is long-time consuming. Moreover, the solid hydrochloride salt of formula (Ib) obtained in toluene is easier to handle than the liquid compound of formula (Ia) and can be directly employed in the following reaction.
  • According to a third embodiment of the present invention, there is provided a process of preparing a compound of formula (V):
  • Figure US20100311967A1-20101209-C00014
  • said process comprising a process described above for any of the first, or second embodiment of the present invention.
  • Compounds of formula (V) are termed herein “Amorolfine base” (RMF base).
  • For example, in order to obtain Amorolfine base, bepromoline HCl (compound (Ib)) can be contacted with, for example, FeCl3, and then added to 2-chloro-2-methylbutane.
  • For example, in order to obtain Amorolfine base, bepromoline base (compound (Ia)) can be converted to bepromoline HCl by a salification step, and then submitted to the same reactions as herein above described (contact with for example FeCl3, and then addition to 2-chloro-2-methylbutane).
  • Typically, the process of the third embodiment further includes the step of reacting a compound of formula (Ib) with 2-chloro-2-methylbutane in the presence of FeCl3 as Friedel-Crafts catalyst.
  • The Friedel-Crafts catalyst will usually be embodiment in a suitable solvent, for example dichloromethane (DCM).
  • Typically, the compound of formula (Ib) is contacted with the Friedel-Crafts catalyst at room temperature.
  • Usually, the 2-chloro-2-methylbutane is added to the compound of formula (Ib) at a temperature of −40° C. to −60° C., for example −50° C.
  • According to a fourth embodiment of the present invention, there is provided a process for preparing a compound of formula (II) (AMF HCl), said process comprising the process of any of first, second, or third embodiments of the invention.
  • In one embodiment, the process for preparing a compound of formula (II) further comprises the step of crystallizing AMF HCl from addition of HCl to a solution of AMF base in ethanol.
  • Typical and usual features of each embodiment of the invention are as for each of the other embodiments of the invention mutatis mutandis.
  • Finally, the present invention features the compound of formula (Ib) (bepromoline HCl):
  • Figure US20100311967A1-20101209-C00015
  • as such, which is produced according to the process as described in the second embodiment of the invention.
  • The present invention also features the compound of formula (Ia) (bepromoline base) or to compound of formula (Ib) (bepromoline HCl), each of these compounds having a purity degree superior or equal to 99.5%.
  • Throughout the specification, unless the context demands otherwise, the terms “comprise” or “include”, or variations such as “comprising” and “including” will be understood to imply the inclusion of a stated feature, or group of features, but not to the exclusion of any other feature, or group of features.
  • In order to further illustrate the present invention and the advantages thereof, the following specific examples are given, it being understood that same are intended only as illustrative and in nowise limitative. In said examples to follow, all parts and percentages are given by weight, unless otherwise indicated.
  • Example 1 Production of Bepromoline HCl
  • a) General Considerations:
  • A mixture of one part of α-methyl-cinnamaldehyde to one part of cis-2,6-dimethyl-morpholine (DMM) is hydrogenated in methanol in the presence of catalytic amount of palladium on carbon, optionally under basic conditions until the uptake of H2 gas ceases, this indicating completion of the reduction of the C═C double bond. Acetic acid is then added for the reduction of the C═N double bond under hydrogen pressure; the C═N double bond is formed between the aldehyde and the amino moiety of the two reactants, α-methyl-cinnamaldehyde and DMM, respectively.
  • The catalyst is then filtered off and the methanol is removed by distillation. Toluene is added and the inorganic components are removed by washing with water. Toluene and unreacted DMM are distilled off. Then fresh toluene and HCl gas are added and the pH is adjusted to 3-4. The bepromoline HCl is centrifuged and dried.
  • Schematic of Production of Bepromoline HCl:
  • Figure US20100311967A1-20101209-C00016
  • Provision of Basic Conditions:
  • Basic conditions were provided by KOH, which is used to neutralize the acidic components present in the α-methyl-cinnamaldehyde. The absence of traces of acid improved the kinetics of the reaction. The reduction of the aldehyde function to the corresponding alcohol is avoided by addition of KOH.
  • Solvent:
  • Methanol may be substituted by toluene to avoid the later solvent exchange step.
  • Temperature of Hydrogenation:
  • 40° C. is the optimum temperature for both hydrogenation steps. However, the temperature may typically be set at no more than 45° C., preferably between 30° C. and 45° C.
  • Acetic Acid:
  • The reduction for the C═N double bond formed between the aldehyde and the amino function of the two components is conducted under hydrogen pressure in acidic conditions after the addition of acetic acid.
  • A molar ratio of acetic acid to KOH is around 1.3 (±10%).
  • The acetic acid is typically added at a temperature range of between 40° C. to 45° C., and no more than 45° C.
  • Toluene Exchange:
  • The toluene is advantageously added to facilitate the phase separations and the distillation step of the unreacted DMM, thus improving the purity of bepromoline.
  • Bepromoline HCl Purity:
  • The trans isomers (VI) and (VII) of bepromoline, coming from trans isomers presents as byproducts in the 2,6-dimethyl morpholine starting material, are partially eliminated during the crystallization of bepromoline HCl.
  • Figure US20100311967A1-20101209-C00017
  • The purity of the bepromoline HCl (cis isomer) is superior or equal to 99.5%.
  • Stability Temperature:
  • The product is stable up to 150° C.
  • b) Synthesis: (Weights are given for 1 kmol α-methyl-cinnamaldehyde).
  • A reactor was charged with 146 kg a-methyl-cinnamaldehyde, 115 kg cis-2,6-dimethyl-morpholine, 2.1 kg 50% KOH, 278 kg methanol and 5.8 kg of a palladium/carbon catalyst and then filled with hydrogen at 15-25° C.
  • The hydrogenation was then conducted at a pressure of ˜2 bar and 35-45° C. until H2 consumption ceased.
  • 1.5 kg acetic acid was then added, and the hydrogenation was re-commenced. The hydrogenation was conducted at a pressure of ˜2 bar and at a temperature of 40-45° C. until no further H2 was consumed.
  • The reaction mixture was filtered and the catalyst washed with methanol and water.
  • The solvents were distilled off at a temperature of up to 95° C. under vacuum.
  • Two extractions were performed using toluene and water. The waste water was drained off.
  • The solvent was then distilled off under vacuum.
  • The reactor was charged with 904 kg toluene and 33 kg HCl gas at a temperature of up to 50° C. Then the pH was adjusted to 3-4. The reaction mixture was cooled and then stored sufficiently to reached complete crystallization.
  • The mixture was centrifuged and washed with cold (0-5° C.) toluene. A second crop of Bepromoline HCl was isolated from the mother liquor.
  • The process yielded 287 kg wet bepromoline HCl, which was then dried at 60° C. under vacuum. After drying, the first crop of Bepromoline HCl was 227 kg and the second 18 kg. This corresponds to a yield of 87% (80% for the first crop Bepromoline HCl and 7% for the second crop).
  • Example 2 Production of Amorolfine Base
  • a) General Considerations:
  • 1 part bepromoline HCl is treated with 1.3 parts FeCl3±5% in dichloromethane at room temperature. The resulting slurry is cooled to approximately −50° C., whereupon 1 to 1.1 parts of 2-chloro-2-methylbutane is added.
  • After an appropriate reaction time of around 2.5 hours, the reaction mixture is poured onto an ice-water mixture. The organic phase is separated and washed with acidic water, and then with sodium phosphate solution and with sodium hydroxide solution. After a stripping with toluene, extractions with water are performed. The solvent is then removed. Then the residue is distilled.
  • Schematic of Production of Amorolfine Base:
  • Figure US20100311967A1-20101209-C00018
  • Reaction Temperature for the addition of FeCl3 to Bepromoline HCl:
  • The addition of FeCl3 to Bepromoline HCl takes place at room temperature. At lower temperatures the subsequent Friedel-Crafts alkylation fails partially or completely (Table 1).
  • TABLE 1
    Bepromoline assay in the
    Temperature (° C.) crude Amorolfine base (%)
    20-30 8-14
     0 14
    −20 100
  • Friedel-Crafts Catalysts:
  • A suitable molar ratio of FeCl3 to bepromoline is 1:2 to 1:5 equivalents of catalyst. 1.3 equivalents of FeCl3 are preferred.
  • Reaction Temperature for Friedel-Crafts Alkylation:
  • To decrease the Fenpropimorph (FPM) byproduct, the reaction is conducted at low temperature, preferably −50° C. (see Table 2):
  • Figure US20100311967A1-20101209-C00019
  • Fenpropimorph (FPM)
  • TABLE 2
    Temperature (° C.) FPM (%)
    −52 to −49 0.14-0.25
    −40 1.7
    −35 2.0
    −20 2.7
  • Fenpropimorph (FPM) is a problematic byproduct as it is difficult to remove from the end product.
  • Ratio of Bepromoline HCl to 2-chloro-2-methylbutane:
  • Batches were performed with 10% excess 2-chloro-2-methylbutane and at a 1:1 ratio. The FPM assay is lower for the 1:1 ratio and thus this proportion is preferred.
  • Phosphate and Alkaline Extraction:
  • The Amorolfine HCl (which is in the DCM) is converted to the free base during these extractions. Phosphate was used to remove traces of Fe.
  • Solvent Exchange:
  • Advantages result if the solvents are exchanged (i.e., toluene in place of DCM): the volume is reduced and the waste-water is contaminated with less chlorinated solvent.
  • Toluene-water Extraction:
  • These extractions are necessary to get the appropriate quality for the subsequent distillation. If these extractions are omitted, the Amorolfine base slightly decomposes at 180° C. The distillation becomes very sluggish and fumes are formed. The vacuum distillation is then not possible at plant scale.
  • The yield was approximately 90% of crude Amorolfine base.
  • b) Synthesis:(weights are given for 1 kmol bepromoline HCl).
  • The reactor was charged with 212 kg FeCl3 and 757 kg DCM. 284 kg bepromoline HCl in 946 kg DCM were added to the reactor at 20-30° C. The reaction mixture was completed with 213 kg DCM and cooled to −50° C. 107 kg 2-chloro-2-methylbutane in 107 kg DCM were added at −50° C., although a temperature of −60 to −45° C. is acceptable, and stirred for 2.5 hours.
  • Hydrolysis was performed using 255 kg ice and 785 kg water.
  • Phase separation was then performed.
  • Extractions using slightly acidic water (water and diluted HCl) were performed, followed by a further extraction with a solution of Na3PO4 in water. A subsequent extraction was conducted using NaOH diluted in water to a pH≧13. At a lower pH value there is incomplete HCl removal, leading to distillation problems. Two washes were performed with water.
  • The solvent was distilled off.
  • Toluene was added and water extractions were performed. Finally the solvent was distilled off under vacuum.
  • This yielded 283 kg crude AMF (approximately 90% AMF base crude)
  • Example 3 Distillation of Amorolfine Base
  • a) General Considerations:
  • The distillation step is necessary to purify Amorolfine Base.
  • Schematic of the Distillation Process:
  • Figure US20100311967A1-20101209-C00020
  • b) Distillation:
  • 283 kg of crude Amorolfine base are distilled at 141°-144° C. under reduced pressure (typically 0.14-0.15 mbar). The fractions are combined in such a way that the impurity profile of the combined material is within the desired specification.
  • After distillation, 190 kg AMF base were produced (approximately 67% AMF base distilled).
  • Example 4 Production of Amorolfine HCl and Evaluation of the Purity of the Produced Compound
  • a) General Considerations:
  • i) Purpose: The goal of this stage is to ensure that sufficient impurities are properly removed with the formation of the Amorolfine HCl and only one crystallization step with ethanol being used.
  • ii) production of Amorolfine HCl with Amorolfine base (salification step): HCl gas is added to a solution of Amorolfine base in two parts of ethanol until the pH reaches 1.5 to 3. The Amorolfine HCl crystallizes at around 45° C. The slurry is cooled to no less than −15° C. (which should take no less than 2 hours). The crude Amorolfine HCl is isolated by centrifugation and washed with cold ethanol. The crude Amorolfine HCl is then recrystallized from two parts of ethanol.
  • Schematic of the Process:
  • Figure US20100311967A1-20101209-C00021
  • Amounts of byproducts in the Amorolfine base:
  • Apart from FPM, all impurities present in AMF base are removed firstly by the salification of AMF base into AMF HCl and secondly by one crystallization step from ethanol.
  • The data given in Table 3 were taken from different crystallization experiments.
  • TABLE 3
    Bepromoline (%) FPM (%) Trans-isomers (%)
    AMF base 5 0.25 0.5
    AMF HCl crude 0.3 0.25 0.3
    AMF HCl <0.1 0.25 <0.2
    Required spec. <0.2 <0.3 <0.2
  • Reaction Temperature:
  • During the addition of the HCl gas, the temperature raises by around 35° C. This exotherm is used to warm the batch. After the addition of HCl the temperature is raised to a level that ensures that the reaction mixture is in solution.
  • The final temperature of −20 to −15° C. is important to obtain an optimum yield.
  • Recrystallization of the Amorolfine HCl:
  • Ethanol is the preferred solvent. The Amorolfine HCl is dissolved in hot ethanol and this solution is filtered to remove foreign matter. The filtrate is then cooled to −15 to −20° C. to get the optimum yield of crystallization. After centrifugation, the crystals are washed with an appropriate amount of ethanol.
  • Drying:
  • The Amorolfine HCl is stable up to 150° C. Drying conditions of 60° C. in a vacuum are used and do not 25 produce any problems with the residual solvent.
  • b) Synthesis: (Weights are given for 1 kmol AMF base).
  • The reactor was charged with 317 kg AMF and 640 kg ethanol. 38 kg HCl gas was added at 10-65° C. The reaction mixture was then heated to 60° C., followed by cooling to −15 to −20° C. The mixture was stored for 30 minutes to 2 hours.
  • The Amorolfine HCl was centrifuged and washed with 210 kg of ethanol.
  • 2 parts ethanol were used to dissolve the Amorolfine HCl at 70-80° C.
  • The hot solution was filtered and the filter rinsed. with 15 kg hot ethanol. The filtrate was then cooled to −15 to −20° C. and stored for 30 minutes to 2 hours.
  • The crystallized Amorolfine HCl was centrifuged and washed with 210 kg of ethanol.
  • The mixture was then dried at a temperature of 60° C. under vacuum (<100 mbar).
  • This yielded 271 kg AMF HCl. The yield was approximately 77%.
  • Each patent, patent application, publication, text and literature article/report cited or indicated herein is hereby expressly incorporated by reference in its entirety.
  • While the invention has been described in terms of various specific and preferred embodiments, the skilled artisan will appreciate that various modifications, substitutions, omissions, and changes may be made without departing from the spirit thereof. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the following claims, including equivalents thereof.

Claims (7)

1. A process for the preparation of a compound of formula (Ib):
Figure US20100311967A1-20101209-C00022
comprising contacting a compound of formula (Ia):
Figure US20100311967A1-20101209-C00023
with toluene and HCl gas to provide said compound of formula (Ib).
2. The process as defined by claim 1, wherein said toluene and HCl gas are added to the medium of reaction at a temperature of up to 50° C.
3. The process as defined by claim 1, further comprising one or more of the following steps:
(a) purifying the compound of formula (Ia);
(b) adding fresh toluene and HCl gas;
(c) adjusting the pH to 3 to 4;
(d) cooling to 0 to 5° C.;
(e) stirring for at least 1 hour; and
(f) isolating the end product of formula (Ib).
4. A process for the preparation of a compound of formula (V):
Figure US20100311967A1-20101209-C00024
comprising contacting a compound of formula (Ib):
Figure US20100311967A1-20101209-C00025
with FeCl3 and then 2-chloro-2-methylbutane.
5. A process for the preparation of a compound of formula (II):
Figure US20100311967A1-20101209-C00026
comprising contacting a compound of formula (V):
Figure US20100311967A1-20101209-C00027
with HCl.
6. The compound of formula (Ia):
Figure US20100311967A1-20101209-C00028
having a degree of purity of at least 99.5%.
7. The compound of formula (Ib):
Figure US20100311967A1-20101209-C00029
having a degree of purity of at least 99.5%.
US12/858,273 2005-07-28 2010-08-17 Production of bepromoline Active 2026-10-09 US8242268B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/858,273 US8242268B2 (en) 2005-07-28 2010-08-17 Production of bepromoline

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP05291611.1 2005-07-28
EP05291611 2005-07-28
EP05291611A EP1749826A1 (en) 2005-07-28 2005-07-28 Process of producing bepromoline
PCT/IB2006/003362 WO2007012984A2 (en) 2005-07-28 2006-07-27 Process of producing bepromoline
US12/010,635 US7795425B2 (en) 2005-07-28 2008-01-28 Production of bepromoline
US12/858,273 US8242268B2 (en) 2005-07-28 2010-08-17 Production of bepromoline

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/010,635 Division US7795425B2 (en) 2005-07-28 2008-01-28 Production of bepromoline

Publications (2)

Publication Number Publication Date
US20100311967A1 true US20100311967A1 (en) 2010-12-09
US8242268B2 US8242268B2 (en) 2012-08-14

Family

ID=35064906

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/010,635 Active 2027-06-22 US7795425B2 (en) 2005-07-28 2008-01-28 Production of bepromoline
US12/858,273 Active 2026-10-09 US8242268B2 (en) 2005-07-28 2010-08-17 Production of bepromoline

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/010,635 Active 2027-06-22 US7795425B2 (en) 2005-07-28 2008-01-28 Production of bepromoline

Country Status (12)

Country Link
US (2) US7795425B2 (en)
EP (2) EP1749826A1 (en)
AR (1) AR054873A1 (en)
BR (1) BRPI0613307B8 (en)
CA (1) CA2616160C (en)
CY (1) CY1113779T1 (en)
DK (1) DK1912961T3 (en)
ES (1) ES2399245T3 (en)
PL (1) PL1912961T3 (en)
PT (1) PT1912961E (en)
SI (1) SI1912961T1 (en)
WO (1) WO2007012984A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1749826A1 (en) * 2005-07-28 2007-02-07 Galderma S.A. Process of producing bepromoline
EP1935889A1 (en) * 2006-12-21 2008-06-25 Galderma S.A. Process of producing amorolfine
ITFI20090032A1 (en) * 2009-02-20 2010-08-21 Synteco S P A Prodotti Di Sintesi Per L Ind INDUSTRIAL PRODUCTION PROCESS OF CHLORIDATED AMOROLFIN
WO2011066735A1 (en) * 2009-12-01 2011-06-09 Zhejiang Hisoar Pharmaceutical Co., Ltd An Amorolfine HCl Crystal and the Preparation thereof
CN102887872B (en) * 2011-12-30 2015-06-24 浙江海翔药业股份有限公司 Method for preparing amorolfine hydrochloride
CN109232458A (en) * 2018-06-15 2019-01-18 南通常佑药业科技有限公司 A kind of preparation method of chirality morpholinium compound

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046280A (en) * 1955-11-24 1962-07-24 Philips Corp Primary, secondary and tertiary amines having a spasmolytic effect and method of producing these compounds
US4202894A (en) * 1976-11-22 1980-05-13 Hoffmann-La Roche Inc. Piperidines morpholines, etc., and fungicidal compositions thereof
US4283534A (en) * 1979-04-11 1981-08-11 Basf Aktiengesellschaft Reductive alkylation of nitrogen heterocycles
US7795425B2 (en) * 2005-07-28 2010-09-14 Galderma S.A. Production of bepromoline
US8049007B2 (en) * 2006-12-21 2011-11-01 Galderma S.A. Preparation of amorolfine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2656747C2 (en) * 1976-12-15 1984-07-05 Basf Ag, 6700 Ludwigshafen Morpholine derivatives
ZW15780A1 (en) 1979-08-17 1981-03-18 Hoffmann La Roche Heterocyclic compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046280A (en) * 1955-11-24 1962-07-24 Philips Corp Primary, secondary and tertiary amines having a spasmolytic effect and method of producing these compounds
US4202894A (en) * 1976-11-22 1980-05-13 Hoffmann-La Roche Inc. Piperidines morpholines, etc., and fungicidal compositions thereof
US4283534A (en) * 1979-04-11 1981-08-11 Basf Aktiengesellschaft Reductive alkylation of nitrogen heterocycles
US7795425B2 (en) * 2005-07-28 2010-09-14 Galderma S.A. Production of bepromoline
US8049007B2 (en) * 2006-12-21 2011-11-01 Galderma S.A. Preparation of amorolfine

Also Published As

Publication number Publication date
EP1749826A1 (en) 2007-02-07
BRPI0613307B1 (en) 2021-04-06
CA2616160C (en) 2014-02-11
AR054873A1 (en) 2007-07-25
BRPI0613307B8 (en) 2021-05-25
SI1912961T1 (en) 2013-04-30
US8242268B2 (en) 2012-08-14
WO2007012984A2 (en) 2007-02-01
US7795425B2 (en) 2010-09-14
WO2007012984A3 (en) 2007-06-14
CY1113779T1 (en) 2016-07-27
DK1912961T3 (en) 2013-02-11
BRPI0613307A2 (en) 2010-12-28
EP1912961B1 (en) 2012-12-05
ES2399245T3 (en) 2013-03-26
CA2616160A1 (en) 2007-02-01
PL1912961T3 (en) 2013-04-30
EP1912961A2 (en) 2008-04-23
US20080269483A1 (en) 2008-10-30
PT1912961E (en) 2013-02-04

Similar Documents

Publication Publication Date Title
US8242268B2 (en) Production of bepromoline
CA2601149C (en) Process of producing amorolfine
US8049007B2 (en) Preparation of amorolfine
KR101083147B1 (en) Process for iohexol manufacture
US20090156802A1 (en) Quetiapine Hemifumarate Purification by Crystallization
US6399829B1 (en) Synthesis and purification of (r*,r*)-2-[ (dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride
US20220064102A1 (en) Process for preparation of highly pure fingolimod hydrochloride
US6262308B1 (en) Process for the preparation of racemic sertraline
JP2017505302A (en) Improved process for producing trazodone and its hydrochloride
US6307103B1 (en) Process for the preparation of 1,1,1-trifluoro-2-aminoalkanes
EP2279998B1 (en) Synthesis of iodixanol in propyleneglycol
US7462718B2 (en) Process for the production of high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarate and high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarate
EP2277852B1 (en) Synthesis of iodixanol in water
US20040242879A1 (en) Process for preparing 1-methyl-3-phenylpiperazine using a novel intermediate
EP1044960B1 (en) Process for the preparation of 1,1,1-trifluoro-2-aminoalkanes
KR100342919B1 (en) A preparation and purification for trans isomer of tramadol hydrochloride
US20050176963A1 (en) Method of producing biperiden I
JP2008308458A (en) Production method of pyridinecarbonyl compound

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

AS Assignment

Owner name: GALDERMA HOLDING SA, SWITZERLAND

Free format text: CHANGE OF NAME;ASSIGNOR:NESTLE SKIN HEALTH S.A.;REEL/FRAME:057698/0356

Effective date: 20200129

Owner name: NESTLE SKIN HEALTH S.A., SWITZERLAND

Free format text: ASSET TRANSFER AGREEMENT;ASSIGNOR:GALDERMA S.A.;REEL/FRAME:057698/0295

Effective date: 20160210

AS Assignment

Owner name: GALDERMA HOLDING SA, SWITZERLAND

Free format text: CHANGE OF ADDRESS;ASSIGNOR:GALDERMA HOLDING SA;REEL/FRAME:060541/0374

Effective date: 20220217

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12